Five Japanese life sciences giants pharma alliances with the Bill and Melinda Gates Foundation and Japan’s government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries.
Astellas Pharma, Daiichi Sankyo, Eisai, Shionogi, and Takeda Pharmaceutical, five top big pharma companies, have joined the Gates foundation and Japanese officials to launch the Global Health Innovative Technology fund.
The fund has three stated purposes: facilitating R&D global partnerships between Japanese and non-Japanese private and public research organizations; providing grants to those R&D global partnerships; and advancing and strengthening Japan’s contribution to global health.
Takeda said in its statement that its participation in GHIT is part of a broader commitment “to solve the social challenges in healthcare where the company can leverage its own expertise.” Toward that end, Takeda said, it is also supporting efforts of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) and Plan Japan to improve access to healthcare for people in developing countries.
Daiichi Sankyo said in its statement that its involvement in GHIT paralleled the company’s individual global-health efforts, which include establishing mobile healthcare field clinics service in India, Cameroon, and Tanzania, to developing countries.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Astellas , Daiichi Sankyo, Eisai, Shionogi, and Takeda
Related report: Partnering Deals and Alliances with Big Pharma
Read: more on bigpharma deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View:Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View:Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity